Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC (ADAP): 8 pipeline candidates · ~4 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.7 months
D/E -2.84 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for Adaptimmune Therapeutics PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$27.8M
Quarterly Burn
$34.8M
Runway
3.7 mo
Revenue
$13.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| adp-520 | Preclinical |
| adp-600 | Preclinical |
| autologous genetically modified afpᶜ³³²t cells | Phase 1 |
| autologous genetically modified mage a10ᶜ⁷⁹⁶t cells | Phase 1 |
| autologous genetically modified t cells | Phase 1 |
| lete-cel | Phase 2 |
| tecelra | Approved |
| uza-cel | Phase 1 |
Frequently asked questions
How many drug candidates are in Adaptimmune Therapeutics PLC's pipeline?
Adaptimmune Therapeutics PLC (ADAP) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adaptimmune Therapeutics PLC's lead drug candidate?
Adaptimmune Therapeutics PLC's most advanced tracked candidate is adp-520 (Preclinical) for CD70-expressing hematological malignancies and solid tumors.
What is Adaptimmune Therapeutics PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adaptimmune Therapeutics PLC has approximately 3.7 months of cash runway.
Who is the CEO of Adaptimmune Therapeutics PLC?
Euronext Growth is the chief executive officer of Adaptimmune Therapeutics PLC (ADAP).
Get the full picture on Adaptimmune Therapeutics PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.